AbbVie has secured European Union approval for Boey, a short-acting botulinum toxin designed for faster onset and shorter duration than traditional formulations. The product represents Allergan's answer to market demand for flexibility in toxin dosing and patient preference for reversibility.
Regulatory
AbbVie Wins EU Approval for Boey, Its Short-Acting Botulinum Toxin
Allergan's rapid-onset neuromodulator clears European regulatory hurdle, expanding the toxin portfolio beyond standard-duration products.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |